Nottingham Advisors Inc. Reduces Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Nottingham Advisors Inc. lessened its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 47.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 97,828 shares of the biopharmaceutical company's stock after selling 87,938 shares during the quarter. Nottingham Advisors Inc. owned about 0.06% of Ocular Therapeutix worth $835,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Wellington Management Group LLP boosted its stake in Ocular Therapeutix by 1.0% during the fourth quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company's stock valued at $3,991,000 after buying an additional 4,488 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Ocular Therapeutix by 123.6% during the fourth quarter. JPMorgan Chase & Co. now owns 189,295 shares of the biopharmaceutical company's stock valued at $1,617,000 after purchasing an additional 104,650 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in Ocular Therapeutix by 26.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock valued at $11,398,000 after purchasing an additional 278,610 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Ocular Therapeutix by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock worth $72,453,000 after buying an additional 99,730 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Ocular Therapeutix during the 4th quarter valued at about $149,000. 59.21% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. JMP Securities set a $19.00 price target on Ocular Therapeutix in a report on Tuesday, March 4th. William Blair started coverage on Ocular Therapeutix in a report on Tuesday. They issued an "outperform" rating for the company. Royal Bank of Canada started coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target for the company. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $16.38.

Ocular Therapeutix Stock Down 0.1 %

Shares of OCUL stock traded down $0.01 during trading hours on Tuesday, reaching $6.30. 385,970 shares of the company's stock were exchanged, compared to its average volume of 1,559,173. The stock has a market cap of $1.00 billion, a PE ratio of -4.77 and a beta of 1.49. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock's fifty day moving average price is $7.39 and its two-hundred day moving average price is $8.67. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The business had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Research analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock valued at $283,772 in the last ninety days. Insiders own 3.50% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.